Community Benefit of No-charge Calcium Score Screening Program

Status Recruiting

Clinical Trial Summary

Current approaches in primary prevention for cardiovascular disease are based on probabilistic approaches to estimate risk, using many of the widely available cardiovascular risks scores, with over 100 such scoring systems currently available throughout the world. The rationale for this practice is to select those individuals at greatest risk for more intense targets, reduce risk of treatment to those at minimal risk, and to maximize the cost-effectiveness of treatment. A recent Cochrane Systematic Review assessed the practice of using risk scores to select individuals for the primary prevention of cardiovascular disease. 3 The principal finding of the systematic review was that there was little or no effect of providing clinicians with cardiovascular risk scores when compared to standard of care (5.4% versus 5.3%; relative risk 1.01, 95% confidence intervals 0.95 to 1.08). The authors concluded that there is major uncertainty whether current strategies for providing risk scores and called for further research to address this concern. Extent of coronary artery calcium (CAC) is a strong risk marker for coronary events, with evidence mainly derived from observational studies and from prospective non-randomized studies. CAC, although endorsed for intermediate risk patients, is not widely adopted due to barriers in reimbursement. The cost of the test ranges between 100 and 300 USD in the United States, which may have limited the wide adoption of the test. Whether reducing the cost burden for CAC increases utilization for routine screening and its influence on physician practices and downstream testing is largely unknown. University Hospitals started offering low charge CAC (99$) since 2014. In 2017, University Hospitals started offering CAC for no charge for patients to improve access to this test, which has not traditionally been covered by insurance companies. The impact of no-charge CAC has never been studied.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiovascular Risk Factor

Clinical Trial Details

NCT number	NCT04075162
Study type	Observational [Patient Registry]
Source	University Hospitals Cleveland Medical Center
Contact	Sadeer Al-Kindi, M.D.
Phone	2168441000
Email	sadeer.alkindi@uhhospitals.org
Status	Recruiting
Phase
Start date	January 2014
Completion date	December 2032

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03644524` - Heat Therapy and Cardiometabolic Health in Obese Women	N/A
Enrolling by invitation	`NCT04253054` - Chinese Multi-provincial Cohort Study-Beijing Project
Completed	`NCT03680638` - The Effect of Antioxidants on Skin Blood Flow During Local Heating	Phase 1
Recruiting	`NCT04481503` - Transthoracic Echocardiography of Ventricular Function of Parturients in Labor
Terminated	`NCT04088240` - Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease	N/A
Completed	`NCT03410342` - The Effects of Types of Fruits and Vegetables on Vascular Function	N/A
Completed	`NCT03170752` - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)	N/A
Recruiting	`NCT04231838` - Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems	N/A
Active, not recruiting	`NCT03902431` - Translating the ABCS Into HIV Care	N/A
Terminated	`NCT03517111` - The Impact of a Parenting Intervention on Latino Youth Health Behaviors	N/A
Completed	`NCT04562467` - The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk	Phase 4
Completed	`NCT03429920` - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors	N/A
Completed	`NCT04551872` - RESILIENCE: Personalizing Cardiovascular Health	N/A
Enrolling by invitation	`NCT03314818` - Natural History of Carotid Plaque as Determined by 3D Ultrasound	N/A
Completed	`NCT03060811` - Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults	N/A
Completed	`NCT04279704` - Overcoming Obstacles in Epigenetic Analysis of Human Twins
Completed	`NCT01050205` - The Healthy Lifestyle Project	N/A
Completed	`NCT03570840` - Pediatric Metabolic Syndrome Study
Completed	`NCT03039023` - Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans	N/A
Completed	`NCT03646175` - Choline Supplementation and Cardiovascular Health	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Community Benefit of No-charge Calcium Score Screening Program — CLARIFY

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms